We assessed replication and excretion of the live attenuated tetravalent dengue vaccine (CYD-TDV) into biological fluids following vaccination in dengue-naive adults in Australia.
Registration of CYD-TDV (Dengvaxia, Sanofi Pasteur), a live-attenuated, tetravalent dengue vaccine, was based mainly on the efficacy and safety demonstrated in 2 pivotal phase 3 clinical trials undertaken in Latin America and Southeast Asia [1, 2] . The pooled CYD-TDV efficacy over the first 25 months after the first vaccination varied by serotype, ranging from 47.1% (95% confidence interval [CI], 31.3%-59.2%) for serotype 2 to 83.2% (95% CI, 76.2%-88.2%) for serotype 4 among participants who were ≥9 years of age (ie, the indicated population) [3] . Longer-term surveillance of the participants in these 2 studies is ongoing to further define vaccine efficacy and safety over time.
As CYD-TDV is a live viral vaccine, the theoretical risk to human health from any live vaccine viruses spreading to the environment needs to be assessed [4] [5] [6] [7] [8] . The in vivo behavior of CYD-TDV can be assessed by evaluating vaccinal viremia and shedding [9, 10] . Vaccinal viremia following injections of CYD-TDV was initially assessed in 867 participants in 7 phase 1/2 studies assessing the timing, peak level, and duration of viremia [11] [12] [13] [14] [15] [16] [17] . Viral shedding was also assessed in 1 phase 1 study after injection 1, but no information was reported in the publication [11] . In 3 of these phase 1 trials (318 participants), viremia occurred most frequently after injection 1 but at low levels [11] [12] [13] . Serotype 4 was the most frequently identified serotype in 4 phase 1/2 [11] [12] [13] [14] , and 2 phase 3 studies [18, 19] . There was no evidence of a relationship between viremia and the occurrence of adverse events in any of these trials.
It is not clear whether variance in serotype-specific viremia may be related to the variance in serotype-specific efficacy profile observed in the 2 phase 3 studies with CYD-TDV; it is generally assumed that vaccinal viremia is indicative that the vaccine is performing as anticipated and leads to the development of protective immunity. Although cellular immune responses against serotype 4 dominate after the first CYD-TDV dose (consistent with the vaccinal viremia profile), the vaccine also induces CD4 + T-cell (T-helper type 1) responses specific to anti-dengue virus serotype and CD8 + T-cell responses specific to anti-yellow fever virus 17D NS3 [20, 21] . As such, underlying dengue virus preimmunity or subsequent CYD-TDV doses induce broader cell-mediated immune responses against all 4 serotypes.
Vaccine safety and the consistency of immune responses for 3 consecutive lots of vaccine produced by the phase 3 scaled-up CYD-TDV production process relative to earlier preparations (ie, the phase 2 vaccine lot) have previously been reported for flavivirus-naive adults from dengue-nonendemic areas in Australia [22] . We present here the results of a substudy in 103 participants at 2 study sites of CYD-TDV viremia and virus shedding after each injection. This is the first publication with shedding data after CYD-TDV use.
METHODS

Study Design and Participants
The study design, inclusion and exclusion criteria, and vaccination schedule for the main study are described previously (clinical trials registration NCT01134263) [22] . The study was conducted in accordance with the Declaration of Helsinki and the International Conference on the Harmonization guideline on good clinical practice. Study protocol and amendments were approved by the respective institutional review boards or independent ethics committees at each study site. Written informed consent was obtained from all participants.
Eligible healthy adults (age range, 18-60 years) were randomly assigned in a 3:3:3:3:1 ratio to receive vaccine from 1 of 3 phase 3 lots, 1 phase 2 lot, or placebo (0.9% NaCl), respectively. Participants received 3 doses of assigned vaccine or placebo subcutaneously at months 0, 6 and 12. The first 52 participants enrolled at each of 2 study sites (Adelaide and Herston, Australia) were selected for additional evaluation of viremia and virus shedding.
Sample Collection
For those enrolled in the viremia and shedding substudy, blood, urine, and saliva samples were collected from each participant at each of 6 time points surrounding each vaccine/placebo injection: immediately before and 6, 8, 10, 14, and 20 days after each injection. Blood samples were collected by venipuncture, allowed to clot for a minimum of 1 hour and a maximum of 2 hours at room temperature, and, optionally, stored for a maximum of 24 hours at 2°C-8°C before centrifugation (2095 × g for 10 minutes). Saliva samples were obtained by chewing for at least 45 seconds on each of 2 Salivette pads (Sarstedt, Nümbrecht, Germany); participants were not to have ingested food, drink, or oral medication within 30 minutes preceding sampling. Salivette pads were centrifuged in a refrigerated centrifuge at 1000 × g for 2 minutes, and recovered saliva was frozen within 30 minutes of sample collection. For urine samples, a minimum of 6 mL of first-stream urine was collected and kept refrigerated (temperature, 2°C-8°C) during transport and centrifugation (1455 × g for 10 minutes). Within 30 minutes of sample collection, 2 aliquots (0.5-1.0 mL) of the resuspended cell pellet were prepared from 3 mL of urine each. All serum (0.5-mL aliquots), urine, and saliva samples were immediately stored at -70°C or lower until analysis. The presumptive presence of CYD-TDV viruses in serum, saliva, and urine samples was initially assessed using a validated qRT-PCR assay at Bio Analytical Research Corporation (Lake Success, NY). qRT-PCR primers used were directed against the core protein gene of the yellow fever virus "backbone" common to all CYD-TDV viruses [23] . Results were expressed as a concentration of log 10 genome equivalents (GEq) per milliliter. The lowest limit of quantification (LLOQ) and the lowest limit of detection (LLOD) of the assay were both 5.16 GEq/mL.
CYD-TDV Serotype-Specific qRT-PCR
YF-PCR-positive serum, urine, and saliva samples were assessed with 4 separate qRT-PCRs, each using serotype-specific primers targeting the envelope-nonstructural protein 1 (NS1) junction gene sequence of each dengue virus serotype [23] . Results were expressed as a concentration of log 10 GEq per milliliter. The LLOQs for the serotype-specific assays were as follows: serotype 1, 5.15 GEq/mL; serotype 2, 5.09 GEq/mL; serotype 3, 5.34 GEq/mL; and serotype 4, 5.46 GEq/mL. The respective LLODs were as follows: serotype 1, 4.70 GEq/mL; serotype 2, 5.09 GEq/mL; serotype 3, 4.82 GEq/mL; and serotype 4, 5.02 GEq/mL.
Sample Size and Statistical Analyses
The analyses in this substudy were descriptive only. Sample size and timing of serum, urine, and saliva sample collection for assessment of viremia and virus shedding were based on data from study CYD04 [11] . That study suggested that the peak viremia level occurs approximately 8 days after CYD-TDV injection; the time points chosen were therefore baseline (day 0), around the peak in viremia level (days 6, 8, 10, and 14) , and late after injection (day 20). In addition, with 104 participants (approximately 96 dengue vaccinees and 8 placebo recipients), quantifiable viremia was expected in at least 13 vaccine recipients after injection 1.
The viremia and virus shedding analysis cohorts were defined for each dose as participants included in the viremia and virus shedding subset who received the dose and provided at least 1 sample for which viremia/virus shedding results were available. Participants were analyzed according to treatment (vaccine lot) received at that dose. For the analysis at any dose, participants were analyzed according to treatment received at the first dose.
RESULTS
Study Population
A total of 103 participants were included in the viremia and shedding analysis cohort, of whom 95 received CYD-TDV: 24, 24, 24, and 23, respectively, received the 3 phase 3 lots or the phase 2 lot, and 8 received placebo (Table 1 ). All 103 participants received the first study injection, 79 (76.7%) received the second, and 74 (71.8%) received the third ( Figure 1 ). Reasons for withdrawal were voluntary withdrawal (13.6% [14] ), noncompliance with protocol (6.8% [7] ), serious adverse event (SAE; 1% [1] ; discussed below), adverse event (AE; 3.9% [4] ), and loss to follow-up (2.9% [3] ). Most withdrawals (65.5% [19 of 29] ) occurred between the first and second injections.
Adherence with injection and sample collection schedules was good. Viremia was detected by YF-PCR in 66 of 95 participants (69.5%) after any injection, with all levels below the LLOQ. CYD-TDV viremia occurred predominantly after injection 1 (<20 days): 65.3% of participants (62 of 95), 5.6% (4 of 72), and 4.5% (3 of 67) had detectable viremia after the first, second, and third injections, respectively. Viremia was mainly observed on days 6-14, with a peak incidence on days 8 and 10 after injection 1 ( Figure 2 ). Viremia was not detected on day 20. Of the 4 participants with viremia after injection 2, only 1 had viremia after injection 1. Among the 3 participants with viremia after injection 3, 2 had previous viremia after injection 1. The number of viremia cases was consistent across the phase 3 lots (lot 1, 12 of 24 cases; lot 2, 18 of 24; and lot 3, 18 of 24) and the phase 2 lot (18 of 23).
One serum sample collected before vaccine administration on the third vaccination day (day 365) from a 27-year-old male had a positive YF-PCR result. This participant also had detectable viremia at days 10 and 14 after injection 1.
CYD-TDV Serotype-Specific qRT-PCR
After any CYD-TDV injection, 52 of 66 YF-PCR-positive participants (78.8%) had viremia of any serotype detected by CYD-TDV serotype-specific qRT-PCR. Of these, 13 of 66 (19.7%) were positive for at least 2 serotypes, and 1 of 66 (1.5%) was positive for 3 serotypes. No participants were positive for all 4 serotypes. The most common combinations of serotypes were serotypes 1 and 4 (7 of 66 participants [10.6%]), and serotypes 3 and 4 (5 of 66 [7.6%] ). All detections were below the LLOQ of the assays for the respective serotypes.
The serotype detected most frequently after any injection was serotype 4 At least 1 serotype was detected in 38 of 48 participants (79.2%) who received the pooled phase 3 lot and in 14 of 18 (77.8%) who received the phase 2 lot, with at least 2 serotypes detected in 7 of 48 (14.6%) and 6 of 18 (33.3%) who received the phase 3 and 2 lots, respectively. The 2 serotypes were predominantly detected in the same serum sample, except for 1 participant in each lot group, for whom the serotypes were identified in different samples. The participant with at least 3 serotypes in the same serum sample had received the phase 2 lot. a DENV neutralizing antibody titers were determined using a 50% plaque reduction neutralization test with parental DENV strains of CYD-TDV constructs (Sanofi Pasteur GCI, Swiftwater, PA) [30, 31] . Baseline DENV seropositivity was defined by DENV neutralization antibodies above the lower limit of quantification [10 × (1/dilution)] for at least 1 serotype.
b Two seropositive participants had viremia detected by yellow fever virus-specific quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and CYD-TVD serotypespecific qRT-PCR after injection 1.
Virus Shedding (in Urine and Saliva)
YF-PCR (Non-Serotype Specific)
Four of ninety-five participants (4.2%; 2 from phase 3 lot 2 and 2 from phase 3 lot 3) had YF-PCR-positive urine samples after any vaccine injection. Of these, 3 (3.2%) followed documented viremia, and 2 (2.1%) were quantifiable (see below). The fourth participant had YF-PCR-positive urine (level, below the LLOQ) on the day of but before the first CYD-TDV injection. This participant did not have detectable viremia at any time point. Three (3.2%) participants had YF-PCR-positive saliva samples; all 3 received the phase 2 lot. Of these, 1 occurred after injection 1 (at day 10), and 1 occurred after injection 3 (at day 14). The first participant with YF-PCR-positive saliva after injection 1 did not have detectable viremia at any time point. The second participant did not have detectable viremia after injection 3 but previously had detectable viremia (serotype 4) at days 8 and 10 after injection 1. The third participant had YF-PCR-positive saliva (level, below the LLOQ) on the day of but before the first CYD-TDV injection. This participant also had detectable viremia (serotype 4) at day 10 after injection 1. No participant had quantifiable viral shedding into saliva.
CYD-TDV Serotype-Specific qRT-PCR
The CYD-TDV serotype was determined in 3 participants with YF-PCR-positive urine samples. The first participant had viremia detected by YF-PCR (level, below the LLOQ) at days 8 and 14 after injection 1, which was undetectable in serotype-specific assays at both time points. Between these time points, this participant exhibited serotype 4 shedding into urine (level, below the LLOQ). The second participant had viremia detected by YF-PCR (level, below the LLOQ) at days 8 and 10 after injection 1, which was undetectable in serotype-specific assays at both time points. At day 14 after injection 1, this participant exhibited quantifiable serotype 3 shedding into urine (level, 5.47 GEq/mL). The third participant had viremia detected by YF-PCR (level, below the LLOQ) at days 6 and 8 after injection 1; the serotype was not detectable at either time point. At day 10 after injection 2, this participant also presented with low-level, quantifiable serotype 3 shedding into urine (level, 5.77 GEq/mL); however, viremia was not detected after injection 2. None of the participants with YF-PCR-positive saliva samples had detectable shedding in serotype-specific assays.
No serum, urine, or saliva sample from the placebo recipients had a positive YF-PCR result.
Safety
The safety findings for the main study have been reported previously [22] . There were no safety concerns with participants who had vaccinal viremia or shedding into urine or saliva. Among the 68 participants with vaccinal viremia or shedding, there were no cases of concomitant fever within 14 days of CYD-TDV injections. However, among participants with vaccinal viremia or shedding, 2 experienced SAEs and 1 experienced a nonserious AE of special interest (rash to chest after injection 1; no fever reported). Of the 2 participants with SAEs, one had 4 episodes of exacerbation of anxiety/depression that started 26 days after injection 1 that required hospitalization and led to discontinuation from the study. The other had pyrexia of unknown cause 161 days after injection 1 that required hospitalization. None of these SAEs or the AE of special interest were considered related to trial product. The overall frequency of SAEs in all participants in this substudy was 3.2% (95% CI, .7%-9.0%), compared with 2.9% (95% CI, .4%-10.2%) in those with vaccinal viremia or shedding.
DISCUSSION
This study confirms that CYD-TDV viruses are well attenuated; our observation that viremia (detected by YF-PCR) could be detected after 65.3% of first doses (62 of 95), 5.6% of second doses (4 of 72), and 4.5% of third doses (3 of 67) was not unexpected. Although vaccinal viremia was detectable, viral loads were too low to be quantified.
Our study was conducted in adults living in dengue-free and yellow fever-free cities of Australia and excluded persons with a history of flavivirus infection or vaccination (yellow fever and/or Japanese encephalitis); only 5 participants in this substudy had dengue virus-neutralizing antibodies detectable at the time of enrollment. The proportion of participants with viremia detected by YF-PCR after injection 1 (65% [62 of 95]) was between that reported in dengue-naive children, adolescents, and adults in Mexico City (up to 45%) [13] and in flavivirus-naive adults in Missouri (79%) after injection 1 (phase 1 lot) [11] . The vaccinal viremia rate in 2-11-year-olds previously vaccinated against yellow fever in Piura, Peru, was reported at 44% after injection 1 (phase 2 lot) [24] and was up to 28% in children, adolescents, and adults in living in the Philippines (phase 1 lot) [12] .
The most frequent serotype detected in serum after any injection was serotype 4 (68.2%), followed by serotype 3 (19.7%). Figure 2. Proportion of participants with non-serotype-specific viremia detected using yellow fever virus-specific quantitative reverse-transcription polymerase chain reaction after injection 1 for pooled phase 3 lots and the phase 2 lot. The number of cases of detectable nonspecific viremia was consistent across the phase 3 lots. This observation in serotype-specific vaccinal viremia following CYD-TDV administration is consistent with other studies with this tetravalent dengue vaccine [11] [12] [13] 24] . Serotype 4 was consistently the most immunogenic in our main study population, producing the highest geometric mean titers (GMTs), followed by serotype 3 [22] . In this substudy, while there was no apparent difference in the GMTs against serotypes 1, 2, and 3 in viremic and nonviremic participants, for serotype 4 the GMT was higher in viremic versus nonviremic participants (Supplementary Figure 1) . This observation needs to be interpreted with caution as the number of participants who did not experience vaccinal viremia was limited.
Interferences between serotypes may, in part, explain why viremia in this study was reported for vaccine serotype 4 in particular; interferences between serotypes has been reported in monkeys [25] and with another candidate dengue vaccine in flavivirus-naive adult volunteers [26] . It is possible that vaccine serotype 4 may be better able to replicate than the other vaccine serotypes in a host when all 4 virus serotypes are administered together. In our main study [22] , we observed that the GMTs 28 days after the third CYD-TDV injection were increased against all 4 serotypes, demonstrating that the vaccine induced an immune response against all 4 serotypes. In addition, a substudy within study CYD28 that looked at cell-mediated immunity in adolescents and adults in Singapore confirmed the importance of 3 vaccinations with CYD-TDV for a broad and persistent T-helper type 1 response against all 4 serotypes [20] that persisted for at least 1 year after the third vaccination.
Vaccinal viremia is consistently more frequently reported after injection 1 than after injection 2 or injection 3 [11] [12] [13] 24] . All vaccine lots assessed had a similar pattern of results and vaccinal viremia kinetics, and these findings were consistent with those observed in adults in other countries where dengue is nonendemic [11] .
The duration of vaccinal viremia observed here is broadly comparable with that reported after the onset of symptoms (2-12 days) from naturally acquired wild-type dengue virus in patients from Jakarta, Indonesia [27] . In our study, there was 1 case of vaccinal viremia (level, below the LLOQ) on the day of the third vaccination but before vaccine administration; it is possible that this may have been a false-positive finding or that it occurred because of (in order of decreasing probability) an error in blood specimen collection or sample labeling, cross-contamination, or laboratory error. Chronic viremia has not been documented in any other studies and is not a likely explanation here.
CYD-TDV shedding into urine or saliva occurred in very few participants. CYD-TDV genome was detected in urine or saliva of 7 participants, but for 2 of the participants, virus detection occurred before the first CYD-TDV injection (1 detection each in a urine and saliva specimen). These cases were also likely potential false positives or due to sample mislabeling, cross-contamination, or laboratory error. All cases of vaccine virus detection in saliva were at levels below the LLOQ. Two of 4 participants with vaccine virus shedding into the urine had levels that were just above the LLOQ. These followed previous documented viremia (level, below the LLOQ) after the same or a previous CYD-TDV injection. Of note, CYD-TDV shedding into urine appears to occur at a lower rate than that following yellow fever vaccination [28] .
The environmental risk of CYD-TDV virus uptake and dissemination by mosquitoes is likely to be very low because of the inability of vaccine viruses to replicate effectively in the mosquito, which thus limits transmissibility by these vectors [29] . This, coupled with the transient low-level or absent CYD viremia observed after vaccination [11] [12] [13] [14] [15] [16] [17] , would make the risk of environmental spread virtually nonexistent. To date, there are no documented reports where dengue virus shedding into urine or saliva has contributed to disease transmission, and, as such, the very low levels of CYD-TDV genome observed in a small proportion of the participants in this study provide additional reassurance against the dissemination of CYD viruses via these routes.
There were no safety concerns for participants with detectable vaccinal CYD-TDV viremia, and no cases of concomitant fever were reported in these participants within 14 days of vaccine injections. There was a higher dropout in this substudy (28.2% [29 of 103 participants]), compared with the main study (13.8% [98 of 712]) [22] , which may have been, in part, due to the long schedule and high frequency of scheduled visits. The viremia substudy cohort included a large proportion of university students, several of whom dropped out following relocation on completion of their studies.
Finally, although it is tempting to try and link the observed variance in serotype-specific viremia in the current study with the available efficacy results from the 2 pivotal phase 3 studies (CYD14 and CYD15), it would not be meaningful to do so for a number of reasons. The current study was undertaken in adults living in a dengue-nonendemic country, and care was taken to avoid recruiting participants planning to travel to dengue-endemic areas during the study period. In contrast, the 2 efficacy studies were undertaken in children living in dengue-endemic countries. Moreover, it is now apparent that prior exposure to wild-type dengue virus infection is an important covariate for efficacy, which increases with age. It is plausible that age is simply indicative of accumulated exposure to dengue, although other factors related to the maturity of the immune physiology of the host cannot be excluded at this time. In addition, the choice to assess virus shedding in a dengue-nonendemic setting was made with the knowledge that vaccinal virus replication is greatest in flavivirus-nonimmune subjects.
In conclusion, vaccinal viremia following CYD-TDV administration occurred in 69.5% of participants (66 of 95) at a low level, below the LLOQ of the PCR assays. Most of the detections of vaccinal viremia were found after the first dose of CYD-TDV, with only a few participants having vaccinal viremia detected after the second or third vaccine injections. Vaccine virus shedding into saliva and urine was observed in very few participants at very low levels. CYD-TDV viremia was not associated with any safety concerns, and none of the participants experienced concomitant fever within 14 days after any CYD-TDV injection.
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